

Practical Concerns of Prescribing Ticagrelor

- ✓ Switching
- ✓ Dyspnea
- ✓ Bleeding
  - intracranial Hemorrhage
  - Gastrointestinal bleeding
- ✓ Inconvenience (twice-daily dosing)

abidi Cardio Thrombosis

Ticagrelor's Adverse Effects and the Risk of Premature Discontinuation



J Am Coll Cardiol. 2019;73(19):2454–64

IR-0922-BRL-7030-SP

2017 DAPT Guidelines

Switching between oral P2Y12 inhibitors

RECOMMENDATION	COR	LOE
In patients with **ACS** who were previously exposed to clopidogrel, switching from clopidogrel to ticagrelor is recommended early after hospital admission at a loading dose of 180 mg irrespective of timing and loading dose of clopidogrel, unless contraindications* to ticagrelor exist.	I	B
Additional switching between oral P2Y12 inhibitors may be considered in cases of side effects/drug intolerance according to the proposed algorithms.	IIb	C

* Contraindications for ticagrelor: previous intracranial hemorrhage or ongoing bleeds.

European Heart Journal (2018) 39, 213–254

Switching Therapy

Switching therapy [2,5]

Reasons for escalating from Clopidogrel to Ticagrelor	Reasons for de-escalation from Ticagrelor to Clopidogrel
ACS patients, who are initially treated with Clopidogrel at presentation: • Patients with either moderate- to high-risk non-ST elevation ACS (NSTE-ACS) (planned for either conservative or invasive management) • STEMI planned for primary PCI	Need for Oral Anticoagulant (OAC)
Admitted with thrombotic event (e.g., stent thrombosis or ACS), who have been treated with Clopidogrel	Bleeding, intolerance
Who are known poor metabolizer of Clopidogrel (e.g., CYP2C19 loss-of-function)	Dyspnea, intolerance
	Triple therapy : OAC + DAPT
	Intolerable side effects

European Heart Journal (2018) 39, 213–254

abidi Cardio Thrombosis

Switching Between Oral P2Y12 Inhibitors

Acute setting:

Clopidogrel → **Ticagrelor LD(180mg)** Irrespective of prior clopidogrel timing & dosing → Ticagrelor

Ticagrelor → **Clopidogrel LD(600mg)** 24h after last ticagrelor dose → Clopidogrel

Chronic setting:

Clopidogrel → **Ticagrelor MD(90mg bd)** 24h after last clopidogrel dose → Ticagrelor

Ticagrelor → **Clopidogrel LD(600mg)** 24h after last ticagrelor dose → Clopidogrel

abidi Cardio Thrombosis

Dyspnea in ACS patients

The most common causes are:

- Heart failure exacerbation
- Pneumonia or acute bronchitis
- Worsening of pre-existing chronic pulmonary disease
- Recurrent ischemia
- Pulmonary thromboembolism
- Anemia
- Side effects of beta-blockers or ticagrelor

✓ **Ticagrelor-related dyspnea diagnosis is based on exclusion**

abidi Cardio Thrombosis

Clin Med Insights Case Rep. 2020;13:1179547620956621

Dyspnea in PLATO study

	Ticagrelor 90mg + Aspirin (N=9235)	Clopidogrel + Aspirin (N=9186)
Overall rate of dyspnea	14%	8%
Mild dyspnea	9.6%	5.5%
Moderate dyspnea	4.5%	2.4%
Severe dyspnea	0.4%	0.2%
Discontinuation of dyspnea	0.9%	0.1%

abidi Cardio Thrombosis

HIGHLIGHTS OF PRESCRIBING INFORMATION reference ID: 4097818

Dyspnea in PLATO sub-study

199 subjects
in a substudy of PLATO

After 1 month/ at least 6 months of chronic treatment

Pulmonary function testing irrespective of reported dyspnea

No indication of an adverse effect on pulmonary function

IR-0122-BRL-6346-SP

HIGHLIGHTS OF PRESCRIBING INFORMATION Reference ID: 4077814

abidi Cardio Thrombosis

Management Of Ticagrelor-related Dyspnea



+Heart failure exacerbation, Pneumonia or acute bronchitis, Worsening of pre-existing chronic pulmonary disease, Recurrent ischemia, Pulmonary thromboembolism, Anemia

IR-0122-BRL-6365-SP

Eur Heart J Acute Cardiovasc Care 2015; 4(6): 555–560.

abidi Cardio Thrombosis

Increased Bleeding Risk



Circulation. 2019;140:240–26

abidi Cardio Thrombosis

IR-0922-BRL-7030-SP

DAPT & Bleeding

- GI hemorrhage is the most common serious bleeding complication from the use of long-term antiplatelet therapy
- Omeprazole & esomeprazole have the highest propensity for clinically relevant interactions with clopidogrel & lansoprazole an intermediate probability
- No interaction between concomitant use of PPIs and prasugrel or ticagrelor

abidi Cardio Thrombosis

Management GI bleeding in DAPT therapy

Measures to minimize bleeding while on dual antiplatelet therapy

Recommendations	Class[a]	Level[b]
Radial over femoral access is recommended for coronary angiography and PCI if performed by an expert radial operator.[43,44]	I	A
In patients treated with DAPT, a daily aspirin dose of 75 - 100 mg is recommended.[45–47,51,52]	I	A
A PPI in combination with DAPT[c] is recommended.[70,79,80,86,87]	I	B
Routine platelet function testing to adjust antiplatelet therapy before or after elective stenting is not recommended.[58–60]	III	A

- PPIs have been recommended for reducing the risk of GI bleeding associated with DAPT.
- Aspirin plus Clopidogrel However, studies have found decreased efficacy of clopidogrel when concurrently administered with a PPI.
- Ticagrelor does not have drug interactions with PPIs.

European Heart Journal (2018) 39, 213–254

abidi Cardio Thrombosis

No significant difference in major fatal/life-threatening **bleeding** with Ticagrelor vs. Clopidogrel

PLATO Study



All values presented by PLATO criteria.
Both groups included aspirin.

N Engl J Med. 2009;361:1045–1057.

abidi Cardio Thrombosis

Twice-daily dosing



British Journal of Clinical Pharmacology 2013; 77(5),: 746-755.

abidi Cardio Thrombosis